News Headlines

  1. Shire Receives U.S. FDA Approval For New State-Of-The-Art Plasma Manufacturing Facility Near Covington, Georgia

    ​Shire plc, the global biotechnology leader in rare diseases, announced recently that the United States Food and Drug Administration (FDA) has approved the company’s first submission for its new plasma manufacturing facility near Covington, Georgia for the production of GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI).

  2. Novacap To Expand Its Pharmaceutical Offering In The U.S. With The Acquisition Of PCI Synthesis

    Novacap, a worldwide player in pharmaceutical synthesis and advanced specialties, announced recently that it has signed an agreement to acquire Boston-based PCI Synthesis, a leading U.S. pharmaceutical contract development and manufacturing organization (CDMO), further reinforcing Novacap’s capabilities and offering for the pharmaceutical industry.

  3. Evotec And Sanofi Sign Definitive Agreement To Combat Infectious Diseases

    Evotec AG recently announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation.

  4. Record Growth At Sterling Pharma Solutions

    A UK-based contract development and manufacturing organisation (CDMO) has more than doubled its sales since its formation in 2016 as demand for its hazardous chemistry capabilities and active pharmaceutical ingredient (API) services grows.

  5. WuXi STA First CDMO To Support The Approval Of An Innovative Drug In China Through The ‘MAH’ Pilot

    STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, announces that its partner, Ascletis has received approval from China Food and Drug Administration (CFDA) of its Category 1 new drug, Ganovo (also known as Danoprevir or ASC08), to treat viral hepatitis C.

  6. Sanofi And Recipharm Announce Transfer Of Holmes Chapel Manufacturing Site

    Recipharm and Sanofi announced recently that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm.

  7. Recipharm Expands Inhalation Capabilities With GBP 45 Million Acquisition Of Sanofi CMO Business Located In UK

    The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market. It also adds additional inhalation commercial drug product manufacturing capabilities, complementing services already offered by Recipharm’s inhalation development facility in the US.

  8. Cambrex Expands Generic API Research And Development Capabilities At Milan, Italy Site

    Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), recently announced that it will expand research and development capabilities at its site in Paullo, Milan, Italy.

  9. WuXi Biologics To Invest $60M To Establish A Biologics Production Facility In The United States

    WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, recently announced that it is to invest $60M and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States.

  10. Wasdell Group Invests £500K In New Microbiological And Analytical Lab

    The Wasdell Group (Wasdell), a leading outsourcing partner to companies within the pharmaceutical, medical device and clinical trials industries, is investing £500k in a new laboratory at its Newcastle site.